In evaluating the predictive value of cfDNA in metastatic breast cancer patients, a large, phase III, ongoing PADA1 study analyzed the ESR1 mutation in 1017 ER+ HER2- patients treated with a first-line aromatase inhibitor plus palbociclib at regular intervals [151]. This evidence concerns the gene ERBB2 and breast carcinoma.